Obesity and cardiovascular diseases (CVD) are major global health challenges, necessitating effective pharmacological interventions. Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has shown potential for significant weight loss and cardiovascular benefits. This systematic review and meta-analysis aim to evaluate the effectiveness of semaglutide in reducing body weight and improving cardiovascular outcomes by synthesizing evidence from interventional studies. A comprehensive search of PubMed, Embase, Cochrane Library, and ClinicalTrials.gov will be conducted to identify randomized controlled trials and interventional studies. Primary outcomes include weight reduction, major adverse cardiovascular events (MACE), glycemic control, and safety. Data will be analyzed using a random-effects model to determine pooled effect estimates. Findings from this study will contribute to understanding semaglutide’s role in obesity and cardiovascular risk management, informing clinical decision-making and future research on its long-term benefits and safety profile.
